Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

756
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
756
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

39
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
39

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-term lessons from MATCH01 macrophage therapy in cirrhosis.

Cell stem cell·2026
Same author

Liver sinusoidal endothelial cell fenestrations in metabolic liver disease: from molecular mechanisms to therapeutic perspectives.

Cell communication and signaling : CCS·2026
Same author

Stress accelerates hepatocellular carcinoma progression via a gut microbial-metabolite axis.

Frontiers in immunology·2026
Same author

Endothelial Hippo pathway regulates the neutrophil niche and lung fibrosis.

Pharmacological research·2026
Same author

Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis.

Nature communications·2026
Same author

Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis.

Cell·2026

相关实验视频

Updated: May 3, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.6K

肺内皮向肺栓塞血栓溶解进行向.

Bi-Sen Ding1, Ying-Jiang Zhou, Xin-Yuan Chen

  • 1Institute of Molecular Medicine and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China.

Circulation
|November 12, 2003
PubMed
概括
此摘要是机器生成的。

一种针对肺内皮的新型抗体-药物结合物证明了肺栓塞的强有力的血栓溶解. 这种向治疗增强了凝块溶解,显著降低了出血并发症的风险.

更多相关视频

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

1.0K
A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

983

相关实验视频

Last Updated: May 3, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.6K
Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

1.0K
A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

983

科学领域:

  • 生物医学工程 生物医学工程
  • 血管生物学 血管生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 肺栓塞 (PE) 是住院患者的常见和危及生命的疾病.
  • 目前用于PE的血栓溶解疗法具有严重出血并发症的高风险.
  • 开发了一种使用肺内皮特异性抗体的新型治疗方法.

研究的目的:

  • 开发和评估针对肺栓塞的有针对性的血栓消化疗法.
  • 评估尿素酶结合剂与肺内皮特异性抗体的疗效和安全性.
  • 为了在临床前模型中比较新型的结合体与未结合的尿激酶.

主要方法:

  • 肺血管内皮膜蛋白质的分离和单克隆抗体 (RE8F5) 的开发.
  • 尿素酶与RE8F5抗体的结合.
  • 在体内生物分布研究和血栓溶解评估在肺,肝脏和下肢栓塞的老鼠模型中.

主要成果:

  • RE8F5抗体及其尿素酶结合体在肺部迅速和特异性积累.
  • 与单独的尿酶相比,尿酶-RE8F5合体在肺栓塞的血栓解毒效率增加了12倍.
  • 结合剂没有影响血纤维素水平或出血时间,与引起显著纤维素消耗的尿酶不同.

结论:

  • 与肺内皮特异性抗体结合的尿酶代表了肺栓塞的有效和安全治疗方法.
  • 这种有针对性的方法提供了高血栓溶解疗效,降低了出血的风险.
  • 与系统性血栓溶解相比,抗体-药物联合体在肺栓塞模型中表现出优异的性能.